Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase
Ligand Pharmaceuticals (LGND) has completed its acquisition of XOMA Royalty (XOMA) for an equity value of about $739 million, the company said Tuesday. XOMA Royalty shareholders received $39 in cash per share and one non-transferable contingent value right tied to a portion of proceeds from certain pending litigation, the company said. Ligand said the acquisition adds seven commercial products, 14 late-stage development programs and more than 100 development and commercial-stage assets. The company said the transaction is expected to add about $0.50 per share and $1.50 per share to its projected adjusted earnings per share in 2026 and 2027, respectively. Ligand said it expects to provide an updated five-year outlook at its Investor Day on Dec. 8. Following the closing, XOMA Royalty's common stock stopped trading on the Nasdaq Global Market, the company said. Price: $307.59, Change: $-1.66, Percent Change: -0.54%
Ligand Pharmaceuticals (LGND) has completed its acquisition of XOMA Royalty (XOMA) for an equity value of about $739 million, the company said Tuesday.
XOMA Royalty shareholders received $39 in cash per share and one non-transferable contingent value right tied to a portion of proceeds from certain pending litigation, the company said.
Ligand said the acquisition adds seven commercial products, 14 late-stage development programs and more than 100 development and commercial-stage assets.
The company said the transaction is expected to add about $0.50 per share and $1.50 per share to its projected adjusted earnings per share in 2026 and 2027, respectively.
Ligand said it expects to provide an updated five-year outlook at its Investor Day on Dec.
8.
Following the closing, XOMA Royalty's common stock stopped trading on the Nasdaq Global Market, the company said.
Price: $307.59, Change: $-1.66, Percent Change: -0.54%